ArticleHuman vaccines & immunotherapeutics2026
Impact of a 21-valent pneumococcal conjugate vaccine on pneumococcal disease incidence among adults 65-84 years of age in Belgium: An epidemiological modeling study.
Article in Human vaccines & immunotherapeutics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Pneumococcal disease (PD) imposes a high clinical and economic burden in Belgium. Effective multivalent vaccines are available and recommended for adults at elevated risk of PD, but do not protect against certain clinically important bacterial serotypes. In response, a new 21-valent pneumococcal conjugate vaccine, PCV21, was designed to protect adults against a greater proportion of pneumococcal disease. This study estimated the impact of implementing PCV21 versus the currently recommended vaccine (PCV20) in Belgium on the incidence of invasive PD (IPD) and non-bacteremic pneumococcal pneumonia (NBPP) among adults aged 65-84 y. We updated a published dynamic transmission model using Belgian data. Model outputs included the annual incidence and cumulative number of cases of IPD, inpatient NBPP, and outpatient NBPP among adults 65-80 and 81-84 over a 15-y time horizon. Adult vaccination using PCV21 was predicted to reduce the incidence and number of PD cases among adults aged 65-84, compared to vaccination using PCV20. Among adults aged 65-80, replacing PCV20 with PCV21 was estimated to reduce the incidence of IPD by 3.68%, inpatient NBPP by 3.08%, and outpatient NBPP by 3.34% by 2036, equating to 134 fewer IPD cases and 1,195 fewer NBPP (inpatient and outpatient) cases over 15 y. Slightly smaller relative differences in disease incidence between vaccination strategies were observed for adults aged 81-84, although PCV21 still prevented substantial additional cases compared to PCV20. Overall, replacing PCV20 with PCV21 in the Belgian adult pneumococcal vaccination program was predicted to avert additional cases of PD among adults 65-84 y.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.